Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
113.90
-1.32 (-1.15%)
At close: Sep 25, 2026, 4:00 PM EDT
112.82
-1.08 (-0.95%)
After-hours: Sep 25, 2026, 7:46 PM EDT
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $481.00M in the quarter ending June 30, 2026, with 47.67% growth. This brings the company's revenue in the last twelve months to $1.66B, up 41.15% year-over-year. In the year 2025, Halozyme Therapeutics had annual revenue of $1.40B with 37.55% growth.
Revenue (ttm)
$1.66B
Revenue Growth
+41.15%
P/S Ratio
7.77
Revenue / Employee
$3,933,187
Employees
423
Market Cap
12.93B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40B | 381.29M | 37.55% |
| Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
| Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
| Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
| Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
| Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
| Dec 31, 2019 | 195.99M | 44.13M | 29.06% |
| Dec 31, 2018 | 151.86M | -164.75M | -52.04% |
| Dec 31, 2017 | 316.61M | 169.92M | 115.84% |
| Dec 31, 2016 | 146.69M | 11.63M | 8.61% |
| Dec 31, 2015 | 135.06M | 59.72M | 79.28% |
| Dec 31, 2014 | 75.33M | 20.54M | 37.47% |
| Dec 31, 2013 | 54.80M | 12.47M | 29.47% |
| Dec 31, 2012 | 42.33M | -13.76M | -24.54% |
| Dec 31, 2011 | 56.09M | 42.46M | 311.67% |
| Dec 31, 2010 | 13.62M | -47.19K | -0.35% |
| Dec 31, 2009 | 13.67M | 4.91M | 55.99% |
| Dec 31, 2008 | 8.76M | 4.96M | 130.66% |
| Dec 31, 2007 | 3.80M | 2.82M | 287.02% |
| Dec 31, 2006 | 981.75K | 854.54K | 671.76% |
| Dec 31, 2005 | 127.21K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.60B |
| BioMarin Pharmaceutical | 3.41B |
| Exelixis | 2.44B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.22B |
| Ascendis Pharma | 1.20B |
| Corcept Therapeutics | 830.81M |
| Axsome Therapeutics | 776.57M |
HALO News
- 7 days ago - Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - PRNewsWire
- 9 days ago - Halozyme announces proposed offering of $1.05B of 2033 convertible senior notes - TheFly
- 9 days ago - Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 - PRNewsWire
- 9 days ago - Halozyme Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 10 days ago - Halozyme Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 14 days ago - Record Revenue Growth Boosts Halozyme Shares - FXEmpire
- 16 days ago - Halozyme Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 23 days ago - Halozyme to Participate at Upcoming Investor Conferences - PRNewsWire